Cost-effectiveness of Rosiglitazone Oral Combination for the Treatment of Type 2 Diabetes in Germany
- 1 November 2006
- journal article
- review article
- Published by Springer Nature in PharmacoEconomics
- Vol. 24 (1) , 35-48
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Modelling EuroQol health‐related utility values for diabetic complications from CODE‐2 dataHealth Economics, 2004
- Cost Effectiveness of Combination Therapy with Pioglitazone for Type 2 Diabetes Mellitus from a German Statutory Healthcare PerspectivePharmacoEconomics, 2004
- Prävalenz des Diabetes mellitus in Deutschland 1998 - 2001DMW - Deutsche Medizinische Wochenschrift, 2003
- Complications, co-morbidity, and blood glucose control in type 2 diabetes mellitus patients in Germany - results from the CODE-2TM studyExperimental and Clinical Endocrinology & Diabetes, 2002
- An economic model of the long-term health care burden of Type II diabetesDiabetologia, 2001
- Kosten des Typ-2-Diabetes in DeutschlandDMW - Deutsche Medizinische Wochenschrift, 2001
- Erhöhter klinischer und wirtschaftlicher Nutzen durch PROSIT (Proteinurie Screening und Intervention) bei Typ 2 diabetischen PatientenDMW - Deutsche Medizinische Wochenschrift, 2000
- Deutsche Empfehlungen zur gesundheitsökonomischen EvaluationMedizinische Klinik, 2000
- The JEVIN trial: A population-based survey on the quality of diabetes care in Germany: 1994/1995 compared to 1989/1990Diabetologia, 1997
- Hyperglycemie and Microvascular and Macrovascular Disease in DiabetesDiabetes Care, 1995